Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant

References

• Ghose A, Elias HK, Guha G, et al. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis-a systematic review of prospective studies. Clin Lymphoma Myeloma Leuk. 2015;15(8):451–457.
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57–68.
   PubMed Web of Science ®Google Scholar
• Gleeson M, Counsell N, Cunningham D, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511–2516.
   PubMed Web of Science ®Google Scholar
• Eyre TA, Djebbari F, Kirkwood AA, et al. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica. 2020;105(7):1914–1924.
   PubMed Web of Science ®Google Scholar
• Puckrin R, El Darsa H, Ghosh S, et al. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. Am J Hematol. 2021;96(7):764–771.
   PubMed Web of Science ®Google Scholar
• Jeong H, Cho H, Kim H, et al. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis. Blood Adv. 2021;5(8):2142–2152.
   PubMed Web of Science ®Google Scholar
• Orellana-Noia VM, Reed D, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139(3):413–423.
   PubMed Web of Science ®Google Scholar
• Lewis K, Jakobsen LH, Villa D, et al. High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-Cell lymphoma: an international retrospective study of 2300 high-risk patients. Blood. 2021;138(Supplement 1):181–181.
   Google Scholar
• Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89(6):1359–1370.
   PubMed Web of Science ®Google Scholar
• Bokstein F, Lossos A, Lossos IS, et al. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma. 2002;43(3):587–593.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Oh SY, Kim JS, et al. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Ann Hematol. 2011;90(5):539–546.
   PubMed Web of Science ®Google Scholar
• Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111(3):1085–1093.
   PubMed Web of Science ®Google Scholar
• Yoo KH, Lee JY, Lim SH, et al. Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma. Acta Haematol. 2015;133(2):179–182.
   PubMed Web of Science ®Google Scholar
• Maciocia P, Badat M, Cheesman S, et al. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy. Br J Haematol. 2016;172(4):545–553.
   PubMed Web of Science ®Google Scholar
• Nagle SJ, Shah NN, Ganetsky A, et al. Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. Int J Hematol Oncol. 2017;6(4):113–121.
   PubMedGoogle Scholar
• Ferreri AJ, Donadoni G, Cabras MG, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015;33(33):3903–3910.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Doorduijn JK, Re A, et al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021;8(2):e110–e121. e21.
   PubMed Web of Science ®Google Scholar
• Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364–370.
   PubMed Web of Science ®Google Scholar
• Chen YB, Batchelor T, Li S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015;121(2):226–233.
   PubMed Web of Science ®Google Scholar
• Bromberg JE, Doorduijn JK, Illerhaus G, et al. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation-an International Primary Central Nervous System Lymphoma Study Group project. Haematologica. 2013;98(5):808–813.
   PubMed Web of Science ®Google Scholar
• Qualls D, Sullivan A, Li S, et al. High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement. Clin Lymphoma Myeloma Leuk. 2017;17(12):884–888.
   PubMed Web of Science ®Google Scholar
• Hassan M, Ehrsson H, Smedmyr B, et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant. 1989;4(1):113–114.
   PubMed Web of Science ®Google Scholar
• Heideman RL, Cole DE, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res. 1989;49(3):736–741.
   PubMed Web of Science ®Google Scholar
• Scordo M, Wang TP, Ahn KW, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021;7(7):993–1003.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–5043.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Williams CD, Pearce R, Taghipour G, et al. Autologous bone marrow transplantation for patients with non-Hodgkin’s lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome-a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol. 1994;12(11):2415–2422.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Wang Z, Zhang MJ, et al. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. Br J Haematol. 2013;162(5):648–656.
   PubMed Web of Science ®Google Scholar
• Kasenda B, Ihorst G, Schroers R, et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia. 2017;31(12):2623–2629.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Damaj G, Ivanoff S, Coso D, et al. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. Haematologica. 2015;100(9):1199–1206.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Min GJ, Park SS, et al. Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas. Bone Marrow Transplant. 2019;54(2):330–333.
   PubMed Web of Science ®Google Scholar
• Schiffman K, Buckner CD, Maziarz R, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin’s disease. Biol Blood Marrow Transplant. 1997;3(5):261–266.
   PubMedGoogle Scholar
• Zaucha R, Gooley T, Holmberg L, et al. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma. 2008;49(10):1899–1906.
   PubMed Web of Science ®Google Scholar
• Sanders S, Chua N, Larouche JF, et al. Outcomes of consecutively diagnosed primary central nervous system lymphoma patients using the Alberta lymphoma clinical practice guideline incorporating thiotepa-busulfan conditioning for transplantation-eligible patients. Biol Blood Marrow Transplant. 2019;25(8):1505–1510.
   PubMed Web of Science ®Google Scholar
• Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012;18(1):76–83.
   PubMed Web of Science ®Google Scholar
• Oh DH, Chua N, Street L, et al. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leuk Lymphoma. 2016;57(1):28–33.
   PubMed Web of Science ®Google Scholar